Innovative Immunological and Target Therapies for NMIBC: Recent Clinical Trial Data Shaping the Future : Episode 8
Opinion
Video
Future of BCG in NMIBC
Author(s):
Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.
Video content above is prompted by the following:
- Given these recent advances and emerging agents, do you think BCG monotherapy will remain the first-line treatment for intermediate-risk and high-risk disease?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Related Content
